Skip to search formSkip to main contentSkip to account menu

recombinant FVIIa

Known as: recombinant FVIIa [Chemical/Ingredient], recombinant coagulation factor viia, FACTOR VIIa,RECOMBINANT 
National Institutes of Health

Related topics

Related topics

10 relations
Blood Coagulation FactorDrug AllergyEnzyme Activators [MoA]Factor VII Deficiency

Broader (2)

Factor VIIaRecombinant Proteins

Narrower (1)

Novoseven

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
Review
2007
Review
2007
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
Summary.  Many patients with haemophilia develop inhibitors to factor VIII and require bypassing agents to provide haemostatic… 
Review
2006
Review
2006
Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery.
Highly Cited
2005
Highly Cited
2005
Recombinant activated factor VII for acute intracerebral hemorrhage.
BACKGROUND Intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality. Among patients… 
Highly Cited
2005
Highly Cited
2005
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease
Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open‐heart surgery… 
Highly Cited
2004
Highly Cited
2004
The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass*
Objective: To assess the hemostatic efficacy of recombinant coagulation factor VIIa (rFVIIa) in the management of uncontrolled… 
Review
2004
Review
2004
Thromboelastography and recombinant factor VIIa-hemophilia and beyond.
Thromboelastography (TEG), which records the continuous profiles of whole blood (WB) coagulation, can be used to evaluate the… 
Highly Cited
2003
Highly Cited
2003
Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa.
Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication that occurs in patients undergoing hematopoietic stem-cell… 
Highly Cited
2003
Highly Cited
2003
Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders
BACKGROUND: Recombinant FVIIa (rFVIIa) has been shown to improve hemostasis in patients with thrombocytopenia and to prevent or… 
Highly Cited
2003
Highly Cited
2003
The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)